Insider Buying: Vanda Pharmaceuticals (NASDAQ:VNDA) Director Acquires $22,051.40 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Duncan bought 5,803 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was purchased at an average price of $3.80 per share, for a total transaction of $22,051.40. Following the transaction, the director owned 108,701 shares of the company’s stock, valued at approximately $413,063.80. This represents a 5.64% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Charles Cliff Duncan also recently made the following trade(s):

• On Wednesday, November 4th, Charles Duncan purchased 3,447 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $13,167.54.
• On Tuesday, November 3rd, Charles Duncan purchased 750 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.80 per share, for a total transaction of $2,850.00.

Vanda Pharmaceuticals Stock Up 6.4%

Shares of VNDA opened at $3.82 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.54. Vanda Pharmaceuticals Inc. has a one year low of $3.57 and a one year high of $9.94. The stock has a market capitalization of $231.00 million, a price-to-earnings ratio of -0.83 and a beta of 0.74. The stock has a 50 day moving average price of $4.63 and a 200 day moving average price of $6.12.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.31. The firm had revenue of $69.81 million during the quarter, compared to the consensus estimate of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -2.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VNDA. Russell Investments Group Ltd. raised its position in Vanda Pharmaceuticals by 3.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 102,282 shares of the biopharmaceutical company’s stock valued at $502,000 after purchasing an additional 2,998 shares in the last quarter. Hsbc Holdings PLC boosted its stake in shares of Vanda Pharmaceuticals by 8.8% in the 1st quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 3,144 shares during the period. Quantbot Technologies LP acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $29,000. Legal & General Group Plc acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $34,000. Finally, Allworth Financial LP acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $43,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analysts Set New Price Targets

VNDA has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial restated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, November 2nd. Zacks Research raised shares of Vanda Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Finally, Oppenheimer started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $13.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.